+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 32 Actively Recruiting clinical trials

B

Actively Recruiting

Researchers are evaluating the effects of aglatimagene besadenovec combined with valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy EBRT. This phase 2a, open-label, multi-center study aims to characterize viral shedding, biodistribution, and immune activation biomarkers to better understand the treatments impact. Approximately 45 participants will be enrolled, with 30 receiving the combination treatment and 15 receiving EBRT alone. Participants in the treatment group will receive three intraprostatic injections of aglatimagene besadenovec, each followed by a 14-day course of oral valacyclovir. EBRT will begin after the second injection. The control group will receive standard or moderately hypofractionated EBRT alone. Biospecimens including blood, urine, and semen will be collected at specific times before and after treatments to assess biodistribution and immune response. Throughout the study, participants will undergo continuous safety monitoring, including assessment of treatment-emergent adverse events and laboratory tests in the treatment group. Biomarkers related to immune activation and tumor burden will be analyzed up to five months after the last injection. The total study duration extends to approximately five months post-treatment, with ongoing evaluation of safety and biological effects.

Age: 18Years +MALEPhase 2
7 locations
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of HBS-301 in adults aged 18 years and older who have idiopathic hypersomnia IH, a condition characterized by excessive daytime sleepiness EDS. This Phase 3 clinical trial is randomized, double-blind, and placebo-controlled, aiming to better understand how HBS-301 affects the severity of sleepiness and other IH symptoms compared to placebo. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may choose to join an optional 1-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by 30 days of safety follow-up after treatment ends. During the trial, participants will have regular assessments including questionnaires measuring sleepiness severity using the Epworth Sleepiness Scale and other scales evaluating IH symptoms, sleep inertia, fatigue, cognition, quality of life, and work productivity. Safety monitoring includes tracking any adverse events throughout the 16 months of the study. Participants will be involved in scheduled visits for evaluations and treatment adherence, with the primary focus on changes in daytime sleepiness severity over the 8-week treatment period.

Age: 18Years +All GendersPhase 3
42 locations
P

Actively Recruiting

Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.

Age: 18Years +All GendersPhase 3
53 locations
L

Actively Recruiting

Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.

Age: 18Years - 50YearsFEMALEPhase 3
120 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
A

Actively Recruiting

Researchers are evaluating an investigational drug called ALN-HSD for adults with Metabolic Dysfunction-Associated SteatoHepatitis MASH, a liver condition marked by fat buildup, inflammation, and scarring that can lead to cirrhosis and liver failure. This Phase 2 study aims to understand how ALN-HSD affects liver scarring and inflammation in participants who have genetic risk factors for MASH. Participants are randomly assigned in a 11 ratio to receive either ALN-HSD or a placebo. The study is double-blind and quadruple-masked, meaning neither participants nor researchers know who receives the active drug or placebo. Treatment is administered according to the study protocol over a period of 52 weeks, with follow-up monitoring extending to 84 weeks to assess safety. During the study, participants will undergo various assessments including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and genetic evaluations. Researchers will track changes in liver fibrosis and inflammation as well as the presence of drug metabolites in blood samples. Safety is monitored throughout the study and beyond the treatment period. The total duration of participation is up to 84 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
71 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of a one-time intravitreal injection of SAR446597 in people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This Phase 12, two-part, multicenter study aims to understand how the treatment works and its potential benefits over approximately two years, followed by an additional three-year extended follow-up period. Participants will receive a single injection of SAR446597 into the eye or a sham injection, depending on the study part and dose group. Multiple dose levels of SAR446597 will be tested in different participant cohorts, with some receiving the active treatment and others receiving a sham as a control. Part I is open-label, while Part II involves randomized dosing and sham control groups. During the study, participants will be monitored for treatment side effects, changes in vision, and the size of GA lesions using visual acuity tests and lesion measurements at baseline, one year, and two years. Safety assessments will continue through the extended follow-up phase. The study also tracks serious and non-serious adverse events up to two years after treatment, with a total study duration of about five years per participant.

Age: 60Years +All GendersPhase 1Phase 2
35 locations
P

Actively Recruiting

Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.

Age: 18Years - 80YearsAll GendersPhase 3
345 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations

1-10 of 32

1